CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioRestorative Therapies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioRestorative Therapies Inc
40 MARCUS DRIVE
Phone: (631) 760-8100p:631 760-8100 MELVILLE, NY  11747  United States Ticker: BRTXBRTX
Business Summary
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYes--

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer LanceAlstodt 52 11/16/2020 11/16/2020
Chief Financial Officer Robert E.Kristal 56 11/4/2021 11/4/2021
Vice President - Quality Assurance/Regulatory Compliance RobertPaccasassi 54 12/1/2021 12/1/2021
4 additional Officers and Directors records available in full report.

Business Names
Business Name
BRTX
BRTXD
BRTXQ
SCLZ
Stem Pearls, LLC
Traxxec, Inc.

General Information
Number of Employees: 11 (As of 12/31/2023)
Outstanding Shares: 6,769,919 (As of 3/28/2024)
Shareholders: 352
Stock Exchange: NASD
Federal Tax Id: 911835664


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024